Drug Trial Radar · NCT03850795
HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Last checked: Nov 20, 2026Latest source record: Aug 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
104
Actual
Start
Mar 15, 2021
Primary completion
Jun 28, 2024
Study completion Jun 28, 2024
Sponsor
- Lead sponsor
- Hinova Pharmaceuticals USA, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 22, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multinational Phase 3, randomized, double-blind, non-inferiority, efficacy and safety study of oral HC-1119 (80 mg/day) versus enzalutamide (160 mg/day) in asymptomatic or mildly symptomatic patients with progressive metastatic castration-resistant prostate cancer (mCRPC). The following assessment of prostate cancer status will be collected during the course of the trial: soft tissue disease on computed tomography (CT) scan or on magnetic resonance imaging (MRI), bone disease on radionuclide bone scans, FACT-P and EQ-5D, Brief Fatigue Inventory, and PSA. Throughout the study, safety and tolerability will be assessed by the recording of adverse events, monitoring of vital signs and physical examinations, safety laboratory evaluations, and 12-lead electrocardiograms (ECGs). Blood samples for population pharmacokinetics for HC-1119 and enzalutamide and related metabolites will be collected.
Conditions
- Prostate Cancer Metastatic
- Castration-resistant Prostate Cancer
Interventions
HC-1119Drug
oral once daily 80 mg
EnzalutamideDrug
oral once daily 160 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR)Time frame: Week 24
Locations
58 sites in 14 countries. Site status is shown where the registry gives one.
Urology Center of Colorado, 2777 Mile High Stadium Circle
Denver, Colorado
Urologic Surgeons of Washington
Washington D.C., District of Columbia
First Urology PSC, 101 Hospital Boulevard
Jeffersonville, Indiana
Clinical Research Solutions PC
Middleburg Heights, Ohio
MidLantic Urology
Bala-Cynwyd, Pennsylvania
Keystone Urology Specialists
Lancaster, Pennsylvania
Urology San Antonio Stone Oak, 18915 Meisner Drive
San Antonio, Texas
Providence Regional Cancer System
Lacey, Washington
Affinity Clinical Research
Nedlands, Australia
Icon Cancer Care Gold Coast
Southport, Queensland, Australia
Ashford Cancer Centre Research
Kurralta Park, South Australia, Australia
Kepler Universitätsklinikum Linz
Linz, Austria
Fe/Male Health Centre
Oakville, Ontario, Canada
CIUSSS de l'Estrie-CHUS
Sherbrooke, Quebec, Canada
Aalborg Universitetshospital
Aalborg, Denmark
Odense Universitetshospital
Odense C, Denmark
Helsinki University Hospital Comprehensive Cancer Center - PPDS
Helsinki, Finland
Oulun Yliopistollinen Sairaala
Oulu, Finland
Seinäjoen Keskussairaala
Seinäjoki, Finland
Tampereen yliopistollinen sairaala
Tampere, Finland
Centre Jean Bernard Clinique Victor Hugo
Le Mans, France
CHRU Lille
Lille, France
Centre Léon Berard
Lyon, France
Centre Hospitalier Lyon Sud
Pierre-Bénite, France
Hopital d'Instruction des Armées de Begin
Saint-Mandé, France
Hopital Foch
Suresnes, Hauts-de-Seine, France
Universitätsklinikum Bonn
Bonn, Germany
Universitätsklinikum Tübingen
Tübingen, Germany
UroGynZentrum Wall
Wuppertal, Germany
Urologische Studienpraxis
Nürtingen, Baden-Wurttemberg, Germany
Azienda Ospedaliera Universitaria Integrata Di Verona
Verona, Italy
Azienda Ospedaliera S Maria Di Terni
Terni, Umbria, Italy
Canisius Wilhelmina Ziekenhuis
Nijmegen, Gelderland, Netherlands
Catharina Hospital
Eindhoven, North Brabant, Netherlands
Antonius Ziekenhuis
Sneek, Provincie Friesland, Netherlands
Hagaziekenhuis
The Hague, South Holland, Netherlands
Onko-Centrum Sp. z o.o.
Lublin, Poland
Urologica Praktyka Lekarska Adam Marcheluk
Siedlce, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy
Warsaw, Poland
Clinical Research Center Spolka z Ograniczona
Poznan, Greater Poland Voivodeship, Poland
Showing 40 of 58 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.